PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
187.54%
Cash & equivalents growing 187.54% while GNPX's declined -61.17%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
187.23%
Below half of GNPX's -61.17%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
168.93%
Below half of GNPX's -50.62%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-20.60%
Both GNPX and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.19%
≥ 1.5x GNPX's -4.04%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
164.96%
Below half of GNPX's -36.31%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-45.35%
1.1-1.25x GNPX's -38.99%. Bill Ackman wonders if the firm relies on extended payables to manage cash flow.
-33.08%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
43.64%
Higher Deferred Revenue (Current) Growth compared to GNPX's zero value, indicating better performance.
-68.51%
Less than half of GNPX's 144.34%. David Dodd sees fewer expansions in other current obligations.
-61.96%
Less than half of GNPX's 13.75%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-61.96%
Less than half of GNPX's 13.75%. David Dodd sees far fewer liability expansions relative to competitor.
19.13%
50-75% of GNPX's 37.22%. Bruce Berkowitz notes minimal new equity relative to competitor.
-3.37%
1.25-1.5x GNPX's -2.94%. Bruce Berkowitz notes stronger reinvestment strategy.
-26.34%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
955.36%
Below half GNPX's -64.03%. Michael Burry sees potential underperformance in building shareholder capital.
164.96%
Below half GNPX's -36.31%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-33.08%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
-197.28%
Less than half of GNPX's 61.17%. David Dodd sees better deleveraging or stronger cash buildup than competitor.